Catalyst Pharmaceuticals (CPRX)
(Delayed Data from NSDQ)
$16.12 USD
+0.10 (0.62%)
Updated Mar 24, 2023 04:00 PM ET
After-Market: $16.12 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
C Value A Growth A Momentum A VGM
Price, Consensus and EPS Surprise
CPRX 16.12 +0.10(0.62%)
Will CPRX be a Portfolio Killer in March?
Zacks Investment Research is releasing its prediction for CPRX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CPRX
Globus Medical (GMED) to Gain From NUVA Deal Amid Rising Costs
Smith & Nephew's (SNN) CIT Technology Favored by New Study
CPRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Syneos Health (SYNH) Partners With KX for Data-Driven Insights
Wall Street Analysts Think Catalyst (CPRX) Could Surge 26.44%: Read This Before Placing a Bet
Henry Schein (HSIC) Bolsters Dental Practices With AI Tools
Other News for CPRX
Catalyst Pharmaceuticals Inc. stock rises Friday, outperforms market
Biotech ETF XBI drops to an 8-month low
Catalyst Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors
Catalyst Pharmaceuticals Inc. stock falls Wednesday, underperforms market
Catalyst Pharmaceuticals Inc. stock rises Tuesday, still underperforms market